Skip to content

Opko Health OPK Net Investment in Lease

Net Investment in Lease at other companies

Quest Diagnostics logo
Quest DiagnosticsDGX
Olema Pharmaceuticals, Inc. logo
Olema Pharmaceuticals, Inc.OLMA
HRO
HarrowHROW
Precigen logo
PrecigenPGEN
Immunome logo
ImmunomeIMNM
Abbott logo
AbbottABT

Other financials

Income statement

See full
Revenue$124.2M-17.2%
Gross profit$45.8M+7.4%
Operating income-$51.0M+24.0%
Net income-$54.8M+18.9%
EPS (diluted)-$0.07+30.0%

Balance sheet

See full
Cash & equivalents$40.6M-62.5%
Total debt$52.8M-4.2%
Total equity$1.2B-8.2%
Total assets$1.9B-12.8%

Cash flow

See full
Operating cash flow-$19.3M+44.1%
CapEx$1.8M-42.6%
Free cash flow-$21.1M+44.0%

Valuation

See full
Market cap$1.13B+10.0%
P/S1.9×+0.5×

Profitability

See full
Gross margin36%+4.2pp
Operating margin-17.4%-5.6pp
Net margin-36.6%-44.8pp
FCF margin-30%+0.1pp

Returns & leverage

See full
Return on equity-16.9%-21.7pp
Debt / equity0.0×
Current ratio3.6×+1.1×

Where this comes from

Reported directly by Opko Health in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The official record: Opko Health’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about Opko Health's net investment in lease.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Opko Health's net investment in lease?
Opko Health (OPK) reported net investment in lease of $45.8M in Q1 2026.
How has Opko Health's net investment in lease changed year-over-year?
Opko Health's net investment in lease decreased by 4.2% year-over-year, from $47.82M to $45.8M.
What is the long-term trend for Opko Health's net investment in lease?
Over 5 years (2020 to 2025), Opko Health's net investment in lease has grown at a 4.5% compound annual growth rate (CAGR), from $37.74M to $46.93M.